Novavax Global Commercial Operations and COVID-19 Vaccine Update

Systemic events in adolescents similar to young adults, regardless of dose PREVENT-19 PRE-fusion Protein Subunit Vaccine Efficacy Novavax Trial | COVID-19 Dose 1 Fever Malaise / Fatigue, Joint Pain Muscle Pain Headache Nausea/Vomiting, 39% 29% 34% 34% 30% 32% Grade 1-2 Grade 3+ 0.7% 7% 7% 8% 10% 0.5% 12-17 18-25 12-17 18-25 12-17 18-25 12-17 18-25 12-17 18-25 12-17 18-25 Dose 2 17% 12% 12-17 18-25 69% 58% 12-17 18-25 61% 62% 57% 49% 24% 16% 12-17 novavax Includes events reported Day 0 to Day 6 post-vaccination; Grades based on FDA guidance 20% 19% 18-25 12-17 18-25 12-17 18-25 12-17 18-25 © 2023 NOVAVAX. All rights reserved. 40

View entire presentation